Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 89.6%

Neg 0% Neu 0% Pos 89.6%

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and raises the price target from $40 to $45.